Christian Holscher is Professor of Neuroscience at the Henan University of Chinese Medicine in China. He previously worked at the department of Biomedical Sciences and Life Sciences at University of Lancaster, England. He did his first degree in Physiology at the University of Tübingen in Germany and continued his career in England, working at several universities such as Oxford University and the Open University. His research is focused on the development of novel drug treatments for Alzheimer’s and Parkinson’s disease. He investigates the interaction between diabetes and neurodegeneration, which led him to discover the neuroprotective properties of incretin hormone analogues which are currently on the market to treat type 2 diabetes. His research techniques include transgenic animal models of Alzheimer’s and Parkinson’s disease to profile new drug candidates in preclinical studies. Liraglutide, one of the drugs profiled by him is now in clinical trials in patients with Alzheimer’s disease and results will be presented at the meeting. He developed novel dual GLP-1/GIP receptor agonists that can cross the blood-brain barrier and show improved neuroprotective effects in animal models of Alzheimer’s or Parkinson’s disease. Clinical trials testing these novel drug candidates are in planning. He is the CSO of Kariya Pharmaceuticals, a biotech company set up to attract investment for drug discovery projects.